Polifarma

Polifarma was founded in 1986 in Istanbul by Pharmacist Necdet Nuri Kumrulu. Today, Polifarma is one of the leading manufacturers of IV drugs and serums in Türkiye.  Polifarma has 500 million units/year medicine and serum production capacity at its modern, EU-GMP-certified production facility, located in Ergene-Tekirdağ, on a 62,000 sqm site.  With over 1,700 employees, Polifarma is committed to adding value to human health by developing innovative and sustainable solutions for hospital and pharmacy products.Polifarma has a broad portfolio in critical therapeutic areas such as parenteral nutrition, anesthesia, nephrology, oncology, infectious diseases, cardiology, and rare diseases.Polifarma exports to more than 50 countries. In addition to being one of the most recognized, recommended, and preferred brands in hospital products, Polifarma is expanding its presence in the pharmacy market as well.As being one of the Türkiye's Top 500 Industrial Enterprises, Polifarma was ranked in the İSO 500 list, Fortune 500 Türkiye, Capital 500 Türkiye lists as well. Polifarma has GMP certificates from 14 different countries’ as well as from Türkiye, also in the process of FDA phase.Polifarma operates across a vast geography spanning Europe, Asia, Africa, and South America, and is approved by international authorities such as the UK MHRA, Australia TGA.As of 2026, Polifarma was ranked among the top 10 pharmaceutical exporters in Türkiye in the “Stars of Export” list by İKMİB.Polifarma’s new R&D facility PolAr-Ge; spanning approximately 11,000 square meters, is set to become one of Türkiye’s most advanced pharmaceutical production and research hubs. Designed with a holistic approach to innovation and operational excellence, the facility will include a state-of-the-art R&D center, modern packaging areas, raw material and drug production zones, as well as administrative offices. The new facility will also feature a GMP-certified Active Pharmaceutical Ingredients (API) synthesis area, further strengthening Polifarma’s capabilities in the field of high-quality pharmaceutical production. Moreover, it will serve as the center for a strategic project focused on the treatment of Spinal Muscular Atrophy (SMA), supported by the Ministry of Industry and Technology under the “Technology-Oriented Industry Initiative Program”. As a company that places innovation at the core of its strategy, Polifarma ranks among the top in Türkiye in terms of R&D investment and performance. Its ‘‘POL R&D’’ center is among Türkiye’s top 250 R&D institutions with the highest number of ongoing projects.It is recognized as:One of the companies with the highest R&D expenditures,One of the organizations conducting the most R&D projects among certified R&D centers.Global Business Models:DistributorshipContract ManufacturingKnow-How & Technology TransferAPI Synthesis & ProductionCo-DevelopmentTurnkey Project ManagementIn-LicensingOut-Licensing & Supply~500 million units/year medicine and serum production capacityGMP Certificates:EU-GMPTürkiyeCambodiaZimbabwePhilippinesLibyaSaudi Arabia - GCCThailandJordanVietnamKenyaSouth KoreaIranAustralia – TGAIn the process of FDA phase.